Abstract
BackgroundA lot of studies have investigated the correlation between x-ray repair cross-complementing group 3 (XRCC3) Thr241Met polymorphism and clinical outcomes in non-small cell cancer (NSCLC), while the conclusion is still conflicting.Materials and MethodsWe conducted this meta-analysis to evaluate the predictive value of XRCC3 Thr241Met polymorphism on response and overall survival of patients with NSCLC. Pooled odds ratios (ORs) and hazard ratios (HRs) and corresponding 95% confidence intervals (95% CIs) were used to estimate the association strength.ResultsA total of 14 eligible studies with 2828 patients were identified according to our inclusion criteria. Meta-analysis results showed that carriers of the variant 241Met allele were significantly associated with good response, compared with those harboring the wild 241Thr allele (Met vs. Thr, OR = 1.453, 95% CI: 1.116–1.892, Pheterogeneity = 0.968 and ThrMet+MetMet vs. ThrThr, OR = 1.476, 95% CI: 1.087–2.004, Pheterogeneity = 0.696). This significant association was observed in Caucasian population but not in Asian population. On the other hand, there was no significant association of XRCC3 Thr241Met polymorphism with survival (ThrMet+MetMet vs. ThrThr, HR = 1.082, 95% CI: 0.929–1.261, Pheterogeneity = 0.564), and there was no difference between Asian and Caucasian population.ConclusionsThese findings suggest a predictive role of XRCC3 Thr241Met polymorphism on response to platinum-based chemotherapy in patients with advanced NSCLC. Additionally, we first report that the XRCC3 Thr241Met polymorphism is associated with response to platinum-based chemotherapy and highlights the prognostic value of the XRCC3 Thr241Met polymorphism.
Highlights
Non-small cell lung cancer (NSCLC) accounts for about 80% of primary lung cancers, most of which were diagnosed at the advanced stage [1]
No evidence of publication bias was detected (p = 0.806 for Begg’s test and p = 0.722 for Egger’s test in dominant model). In this meta-analysis, we provided evidence that, in patients with advanced non-small cell cancer (NSCLC), the variant x-ray repair cross-complementing group 3 (XRCC3) 241Met allele could predict good response to platinum-based chemotherapy, especially in Caucasian population; while there was no significant association of XRCC3 Thr241Met polymorphism with survival
The XRCC3 Thr241Met polymorphism might be a potential biomarker to predict clinical outcomes of NSCLC patients treated with platinum-based chemotherapy and a lot of clinical studies have been conducted to evaluate the predictive value of XRCC3 Thr241Met polymorphism[11,12,23,25]
Summary
Non-small cell lung cancer (NSCLC) accounts for about 80% of primary lung cancers, most of which were diagnosed at the advanced stage [1]. A lot of clinical studies have suggested that genetic factors can influence treatment efficacy of lung cancer and are correlated with prognosis of patients [6,7,8]. Among these genetic factors, single nucleotide polymorphisms (SNPs) in the DNA repair pathway have been mostly investigated. A lot of studies have investigated the correlation between x-ray repair cross-complementing group 3 (XRCC3) Thr241Met polymorphism and clinical outcomes in non-small cell cancer (NSCLC), while the conclusion is still conflicting
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
